LivaNova reported a non-GAAP EPS of $1.26 (+$0.17 vs. expectations) and revenue of $390.6 million (+$10.02 million vs. expectations), delivering a performance surprise. This strong performance, which exceeded market consensus, was announced in pre-market and intraday news. It was officially confirmed through an 8-K filing (Item 2.02).
The quarterly results were not bad, and the magnitude of the beat against consensus seemed significant, making it worth considering an entry as a 'performance momentum play.'
02
INITIAL SCENARIO
AI's Initial Call
Entry Rationale
Based on the entry point (during trading on August 5),
1) There was a performance surprise news,
2) The stock had risen for the previous seven trading days (+9.1%) with a 20-day moving average in a positive alignment, and trading volume was 2.28 times higher, indicating strong demand,
3) The previous day's closing price of $85.32 was just below the previous day's high of $85.76, signaling an imminent breakout above the resistance level.
These three factors aligned to consider either a 'buy after confirming the breakout' or 'entering during an intraday pullback.' However, it should be noted that the target profit price ($85.76) is the same as the previous day's high, which could indicate strong resistance.
Target/Stop Scenario
The target price for taking profit is set at $85.76 (the previous day's high and the value derived from REPORTING), and the stop-loss price is set at $75.3 (the value derived from REPORTING).
- If the closing price settles above $85.76 or breaks through it intraday with confirmed support, take profit will be executed.
- If the closing price falls below $75.3 or experiences a sharp decline intraday touching the stop-loss line, an immediate stop-loss will be triggered.
The technical basis follows the values derived from a separate calculation logic (REPORTING) without further explanation.
Take-profit reference$85.76
Stop-loss reference$75.30
03
TECHNICAL BASELINE
Market Data at Analysis Time
RSI65.6
Vs. Average Volume2.28×
Recent Change+9.1%
MA20$80.94MA60$78.01MA200$66.77
RSI(14) 65.6 → Approaching overbought territory (70) but still has room, maintaining upward momentum
Moving averages in a positive alignment → Both short-term and medium-term trends are upward
Trading volume 2.28 times the 20-day average → Strong buying pressure confirmed
Recent 7-day volatility +9.1% → Possibility of fatigue due to short-term surge also exists
04
HISTORICAL EVIDENCE
Similar Past Cases
All three past similar success cases matched the keyword 'Non-GAAP EPS surprise.'
- BHC (2026-07-31, +28.7%): Non-GAAP EPS 1.26, +0.25 surprise
- THC (2026-07-31, +27.0%): Non-GAAP EPS 6.12, +1.86 surprise
- IESC (2026-07-31, +22.5%): Non-GAAP EPS 6.70, revenue +0.16 billion surprise
Commonality: A strong short-term increase (around 20% range) has been repeatedly observed when a Non-GAAP earnings beat occurred in the healthcare/medical sector. LIVN, being in the same sector, with the same keyword and a similar beat magnitude, was considered as a basis for entry with the expectation of 'pattern repetition.' However, it should be noted that BHC and THC are large hospital and pharmaceutical stocks, while LIVN is a medical device company, indicating a difference in sub-sectors within the industry.
Forecast: Expecting to reach target price of $85.76 (+3.5%)
Actual: Touching stop-loss price of $75.3 (-10.6%) → FAILED
What was correct:
- The earnings beat itself was factual (confirmed by news and 8-K)
- Confirmed technical strength just before entry (bullish alignment, trading volume 2.28 times, +9.1% over 7 days)
- Similar cases (BHC/THC/IESC) also recorded strong increases after a non-GAAP EPS beat
What was missed:
- Entering during the trading day of the earnings announcement carried a significant "sell the news" risk. The previous day's high ($85.76) was the same as the target price, creating strong resistance, and intraday profit-taking led to a gap down and sharp decline
- Entered based on the headline without checking the details of the 8-K (guidance, margins, cash flow, etc.) → Could not later determine why the stock price reaction was lukewarm compared to the earnings content
- The stop-loss price ($75.3) was set deeply at -11% compared to the entry price, creating a greater risk of larger losses while hoping for a rebound before touching the stop-loss in a highly volatile stock
What to Watch in the Next Analysis
1) The entry rule for earnings surprise stocks has been changed from "enter after confirming a breakout during the trading session" to "enter after confirming the initial reaction at the opening price after market close or the next day" — it is essential to check the absorption of 'sell' orders.
2) Even if the profit-taking and stop-loss calculation logic (REPORTING) values are present, if they overlap with the previous day's high and low, consider it as 'resistance/support overlap' and reduce position size by 50% or pass.
3) Automate the scanning of guidance, margin, and cash flow keywords from the original 8-K Item 2.02 disclosure — do not enter based solely on headline beats.
4) During periods of a surge in healthcare theme news, the 'sector beta' is high, so add simultaneous monitoring of sector ETFs (such as XLV) for individual stock risk hedging.
Investment Reference NoticeThis report is a record of past AI analysis being verified — it does not solicit buying or selling any specific stock. All investment decisions and responsibility rest with the user.